In conclusion, the neuroprotective effect of metformin against the PD-R subtype (rapid PD progression) could be attributed to its ability to inhibit neuroinflammation, enhance PI3K/AKT activity for efficient α-synuclein clearance, and stimulate angiogenesis. The gene discussed is AKT1; the disease is Parkinson disease.